{"id":58637,"date":"2026-03-03T13:23:29","date_gmt":"2026-03-03T05:23:29","guid":{"rendered":"https:\/\/flcube.com\/?p=58637"},"modified":"2026-03-03T13:23:30","modified_gmt":"2026-03-03T05:23:30","slug":"sanofis-rilzabrutinib-wins-japan-orphan-designation-for-igg4-rd-btk-inhibitor-expands-rare-disease-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58637","title":{"rendered":"Sanofi’s Rilzabrutinib Wins Japan Orphan Designation for IgG4\u2011RD \u2013 BTK Inhibitor Expands Rare Disease Portfolio"},"content":{"rendered":"\n

Sanofi (NASDAQ:\u202fSNY<\/a>)<\/strong> announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)<\/strong> has granted orphan drug designation (ODD)<\/strong> to rilzabrutinib<\/strong> for IgG4\u2011related disease (IgG4\u2011RD)<\/strong>. The oral, reversible covalent BTK inhibitor<\/strong> is already approved for immune thrombocytopenia (ITP)<\/strong> in the US, EU, and UAE (2025), with regulatory review ongoing for ITP in Japan<\/strong> and multiple expedited designations<\/strong> across rare immune\u2011mediated diseases.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Sanofi (NASDAQ:\u202fSNY)<\/td><\/tr>
Product<\/strong><\/td>Rilzabrutinib<\/td><\/tr>
Drug Class<\/strong><\/td>Oral, reversible covalent BTK inhibitor<\/td><\/tr>
Regulatory Body<\/strong><\/td>Ministry of Health, Labour and Welfare (MHLW), Japan<\/td><\/tr>
Designation<\/strong><\/td>Orphan Drug Designation (ODD)<\/td><\/tr>
New Indication<\/strong><\/td>IgG4\u2011related disease (IgG4\u2011RD)<\/td><\/tr>
Prior Approvals<\/strong><\/td>ITP approved (US, EU, UAE \u2013 2025)<\/td><\/tr>
Under Review<\/strong><\/td>ITP (Japan); additional indications with expedited designations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

IgG4\u2011RD Disease Context<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Disease Nature<\/strong><\/td>Rare, progressive, immune\u2011mediated chronic condition<\/td><\/tr>
Pathophysiology<\/strong><\/td>Immune system attacks multiple tissues\/organs \u2192 serious damage<\/td><\/tr>
Standard of Care<\/strong><\/td>Glucocorticoids (limited efficacy, significant side effects with chronic use)<\/td><\/tr>
Unmet Need<\/strong><\/td>Disease\u2011modifying therapy reducing flare frequency and steroid dependence<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 Phase 2 Study (NCT04520451)<\/h2>\n\n\n\n
Outcome<\/th>Rilzabrutinib Result<\/th><\/tr><\/thead>
Treatment Duration<\/strong><\/td>52 weeks<\/td><\/tr>
Disease Flares<\/strong><\/td>Reduction observed<\/td><\/tr>
Disease Markers<\/strong><\/td>Improvement in biomarkers<\/td><\/tr>
Glucocorticoid Use<\/strong><\/td>Minimized need for steroid treatment<\/td><\/tr>
Safety Profile<\/strong><\/td>Consistent with prior studies in other indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Expedited Designations Portfolio<\/h2>\n\n\n\n
Indication<\/th>Designation Status<\/th><\/tr><\/thead>
Immune Thrombocytopenia (ITP)<\/strong><\/td>Approved (US, EU, UAE); under review (Japan)<\/td><\/tr>
IgG4\u2011Related Disease (IgG4\u2011RD)<\/strong><\/td>ODD (Japan); Phase 2 data positive<\/td><\/tr>
Warm Autoimmune Hemolytic Anemia (wAIHA)<\/strong><\/td>Expedited designation<\/td><\/tr>
Sickle Cell Disease (SCD)<\/strong><\/td>Expedited designation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n